Probiotic Neoantigen Delivery Vectors for Precision Cancer Immunotherapy

Investigators engineered probiotic Escherichia coli Nissle 1917 as an antitumour vaccination platform optimized for enhanced production and cytosolic delivery of neoepitope-containing peptide arrays, with increased susceptibility to blood clearance and phagocytosis.